Crescent Biopharma released FY2024 Q4 earnings on February 13 (EST), actual revenue USD 0, actual EPS USD -19.7395 (forecast EPS USD -16)

Brief Summary

For its fourth fiscal quarter of 2024, Crescent Biopharma reported zero revenue and an earnings per share of -$19.7395, missing the market’s expectation of -$16.

Impact of The News

Event Analysis: Earnings Miss and Pre-Commercial Status